April 30, 2026 · Phase 2 readout
ANRO Phase 2 readout: a positive outcome, +5.6%
On April 30, 2026, Alto Neuroscience, Inc. reached its Phase 2 readout. The result was a positive outcome, and the stock moved +5.6% in the window around the event. It had already run +8.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$24.30
1d before
$25.66
Event day
$24.94
1d after
$25.45
5d after
Our prediction vs. the result
CatalystAlert called this one up (+27.2% expected); the stock actually moved +5.6%. Model confidence at the time: 55%.
See the full scored track recordPre-catalyst setup
+8.0%
30-day run-up
7739%
30-day volatility
0.4×
volume spike